These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 3259620)

  • 21. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
    Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
    J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells.
    Yasumura S; Lin WC; Hirabayashi H; Vujanovic NL; Herberman RB; Whiteside TL
    Cancer Res; 1994 Jul; 54(14):3808-16. PubMed ID: 8033100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA
    J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.
    Melder RJ; Whiteside TL; Vujanovic NL; Hiserodt JC; Herberman RB
    Cancer Res; 1988 Jun; 48(12):3461-9. PubMed ID: 3259468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitory effects of alloimmune T cells on the generation of cytolytic responses of lymphokine-activated killer cells.
    Sugarbaker PH; Matthews W; Steller EP; Eggermont AM
    J Biol Response Mod; 1987 Aug; 6(4):430-45. PubMed ID: 3498012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble glucan and lymphokine-activated killer (LAK) cells in the therapy of experimental hepatic metastases.
    Sherwood ER; Williams DL; McNamee RB; Jones EL; Browder IW; Di Luzio NR
    J Biol Response Mod; 1988 Apr; 7(2):185-98. PubMed ID: 3283299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
    Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
    Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy of murine and human tumors in mice with lymphokines and interleukin-2-propagated lymphocytes.
    Kedar E; Chriqui-Zeira E; Kyriazis AP
    J Biol Response Mod; 1984 Oct; 3(5):517-26. PubMed ID: 6334139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE; Rosenberg SA
    Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
    Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
    Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
    J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
    Steller EP; Ottow RT; Eggermont AM; Marquet RL; Sugarbaker PH
    Cancer Detect Prev; 1988; 12(1-6):81-90. PubMed ID: 3263202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.
    Gregg EO; Gregg IC; Green I
    Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of cellular immunotherapies and anti-CD3 in the treatment of MCA-38-LD experimental hepatic metastases in C57BL/6 mice.
    Gallinger S; Hoskin DW; Mullen JB; Wong AH; Roder JC
    Cancer Res; 1990 Apr; 50(8):2476-80. PubMed ID: 2138507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.
    Mulé JJ; Yang JC; Afreniere RL; Shu SY; Rosenberg SA
    J Immunol; 1987 Jul; 139(1):285-94. PubMed ID: 3108401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eradication of palpable intradermal murine bladder tumors by systemic interleukin-2 and cyclophosphamide in C3H mice.
    Lee K; O'Donnell RW; Marquis D; Cockett AT
    J Biol Response Mod; 1988 Feb; 7(1):32-42. PubMed ID: 3286824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
    Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
    Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
    Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.